Scrip Reports

The Pharmaceutical R&D Compendium: CMR International/Scrip's Complete Guide to Trends in R&D - 2000 Edition
Reference

The Pharmaceutical R&D Compendium CD-ROM is the essential point of reference for everyone involved in researching, developing or marketing new medicines and for those interested in monitoring the performance of companies, products and global pharmaceutical R&D.

Fully revised and updated for 2000, the Pharmaceutical R&D Compendium CD-ROM is divided into 18 chapters, with five brand-new sections covering investment and output in key markets, non-clinical development strategies, drug delivery, drug discovery and the registration of pharmaceuticals in emerging markets.

The Pharmaceutical R&D Compendium CD-ROM is a unique strategic management tool, containing extensively researched, comprehensive industry information - including charts and graphs that can be exported into your own presentations, reports or benchmarking exercises.

The Pharmaceutical R&D Compendium will enable you to:

Benchmark your company's performance against that of the global pharmaceutical industry
Forecast the success of your R&D pipelines
Identify new opportunities for licensing and outsourcing alliances and partnerships
Monitor the R&D activity of your major competitors
Develop new R&D strategies to gain competitive advantage
Adapt your R&D portfolio to optimise your strategies in each major market

Also available in print (800+ pages). For a full table of contents, or details of multiple user prices, please contact our Customer Helpdesk.

Customer Helpdesk

Telephone: +44 (0)20 8332 8965/66

Fax: +44 (0)20 8332 8992

PUBLISHED: July 2000
REF: BS1071E
PRICE: £1,750/$2,995/¥420,000

Contents Summary

R&D Investment and Sales
Reviews companies' R&D expenditure and sales, including forecasts up to 2005.

Investment and Output in Key Markets
NEW
Details R&D investments and productivity of the UK, US and Japanese pharmaceutical markets. The chapter assesses and compares R&D investment and output for these three countries and supplies forecasts to 2003.

Non-clinical Development Strategies
Contains key information on the international pharmaceutical industry's strategies for the safety evaluation of biotechnology products

Clinical R&D Strategies and Culture
NEW
Summarises CMR International 's recent surveys on issues of concern in clinical development, as well as portfolio management and corporate culture.

Drug Delivery Strategies
NEW
Details surveys of 125 drug delivery and 65 pharmaceutical companies. The surveys examine the needs and strategies of both types of companies and evaluates how best to structure co-development deals. This chapter also includes details of current practises and future strategies for drug delivery technologies.

Outsourcing Strategies
Thirty-six companies' current and future strategies for contracting out, including information on CROs

Drug Discovery
NEW
Examines and compares the drug discovery processes of pharmaceutical companies worldwide and shows the existence of a common drug discovery process. The chapter also discusses the impact that the new drug discovery technologies will have on current drug discovery processes.

NASs in Development
Analyses new active substances being developed by 46 leading companies

Preclinical Projects
Provides an overview of early research interests.

Biotechnology Projects
Reviews new data and analyses where biotechnology strategies are currently being used.

Projects by Therapeutic Class
Examines the latest data, highlighting trends in clinical development by therapeutic category.

Licensing Activities
Looks at strategic alliances and analyses which companies have licensed out which compounds.

Company Development Portfolios
Reviews and analyses the latest trends in over 30 leading companies' research pipelines.

Key Benchmarks
Provides updated information and analyses of drug cycle times.

Marketed Medicines
Studies trends in launches of new medicines on the world's major markets.

Development Times
Studies trends, from time of first synthesis of an NME to its launch, for all NMEs coming to market in recent years.

Regulatory Review Times
Summarises CMR International's recent surveys in the regulatory arena, including approval times and review procedures in major markets.

Registration of Pharmaceuticals in Emerging Markets
NEW
Provides an in-depth analysis of the impact of emerging markets on pharmaceutical companies' global development strategies. Includes essential information on strategies for submissions to regulatory authorities and marketing authorisation applications.